(Q44314920)

1 December 2017

title

Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties (English)

1 reference

1 December 2017

1 reference

0 references

Geoffrey L Hammond

1

1 reference

1 December 2017

Larry S Abrams

2

1 reference

1 December 2017

George W Creasy

3

1 reference

1 December 2017

Jaya Natarajan

4

1 reference

1 December 2017

J Glyn Allen

5

1 reference

1 December 2017

Pentti K Siiteri

6

1 reference

1 December 2017

publication date

1 February 2003

1 reference

1 December 2017

1 reference

1 December 2017

volume

67

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

93-99

1 reference

Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μg of norgestimate/35 μg of ethinyl estradiol): Results of an open, multicenter study of 59,701 women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

A norgestimate-containing oral contraceptive: review of clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

A comparison of the potencies and activities of progestogens used in contraceptives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Biotransformation of norgestimate in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Metabolism of norgestimate by human gastrointestinal mucosa and liver microsomes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Determination of norgestimate and its metabolites in human serum using high-performance liquid chromatography with tandem mass spectrometric detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Sex-hormone-binding globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Hormonal contraceptives and plasma sex hormone binding globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Serum distribution of two contraceptive progestins: 3-ketodesogestrel and gestodene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Sex Hormone Binding Globulin : The Carrier Protein For d-Norgestrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

The oestrogenic potency of various contraceptive steroids as determined by their effects on transcortin-binding capacity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Distribution and percentages of non-protein bound contraceptive steroids in human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Crystal structure of human sex hormone-binding globulin: steroid transport by a laminin G-like domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

The affinity of norgestimate for uterine progestogen receptors and its direct action on the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0010-7824%2802%2900473-0

10.1016/S0010-7824(02)00473-0

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference